AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02466867
Drug: Naftin® Cream, 2% (older pediatric cohort)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 4 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 6 to 11 years, 11 months.
Trial: NCT01998620
Drug: Ademetionine 2
RxNorm normalized name: ADEMETIONINE
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ademetionine 1000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 500mg po bid with general antiviral treatment for 8 weeks
Trial: NCT01998620
Drug: Ademetionine 1
RxNorm normalized name: ADEMETIONINE
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ademetionine 2000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
Trial: NCT01998620
Drug: Ademetionine 3
RxNorm normalized name: ADEMETIONINE
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
Trial: NCT00404820
Drug: Zoledronic acid 5 mg solution
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid was supplied as a concentrate of 5.33 mg zoledronic acid monohydrate in a 100 ml solution. 5.33 mg zoledronic acid monohydrate equals 5 mg zoledronic acid.
Trial: NCT00404820
Drug: Calcium/Vitamin D
RxNorm normalized name: CALCIUM/VITAMIN D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined elemental calcium / vitamin D chewable tablets. Participants took 2 tablets a day, for a daily dose of calcium 1200 mg/vitamin D 800 IU.
Trial: NCT02456597
Drug: lidocainhydrochlorid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine injected through the novel Catheter
Trial: NCT02456597
Drug: Isotonic Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline injected through the novel Catheter
Trial: NCT00382239
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection twice daily, 0.02 mL to 0.04 mL
Trial: NCT03581422
Drug: hCG administration before embryo transfer
RxNorm normalized name: human embryo tissue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thawed embryo transfer with ovulation triggered by hCG
Trial: NCT00274937
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00936871
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo single dose
Trial: NCT03995732
Drug: PC-SOD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PC-SOD will be dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
Trial: NCT01682083
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo capsules and tablets contained the same inactive ingredients and film coatings as the dabrafenib and trametinib study treatment
Trial: NCT02134405
Drug: Placebo (for Esomeprazole)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic Esomeprazole
Trial: NCT00778505
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: closed-loop administration using bispectral index as the controller
Trial: NCT00778505
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: manual administration according bispectral index values
Trial: NCT03497897
Drug: LYS006 2 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LYS006 2 mg, capsules, oral administration, BID, for 12 weeks
Trial: NCT03497897
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, capsules, oral administration, BID, for 12 weeks
Trial: NCT00914394
Drug: Physiological saline solution (as placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion period 20 minutes
Trial: NCT01741844
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study. Etravirine 200 mg will be adminstered twice daily in patients with Acquired Immune Deficiency Syndrome (AIDS).
Trial: NCT03995732
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
Trial: NCT00723528
Drug: Placebo A (After CP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), the placebo group will be randomized into 2 groups, including Placebo A, in which ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
Trial: NCT01519804
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching onartuzumab (MetMAb) placebo iv, Day 1 of each 21-day cycle
Trial: NCT00723528
Drug: Placebo B (After CP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), the placebo group will be randomized into 2 groups, including Placebo B, in which ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
Trial: NCT04504396
Drug: GLP-1 receptor agonist
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PB-119 is an investigational pegylated human glucagon-like peptide-1 (GLP-1) receptor agonist. The dosing regimen is 150μg once every week as subcutaneous administration. Patients in PB-119 group will be administered the active drugs for 52 weeks (24+28).
Trial: NCT04504396
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PB-119 matched placebo will be used once every week as subcutaneous administration to placebo group for 24 weeks.
Trial: NCT00511446
Drug: docetaxel, oxaliplatin, capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel: 35 mg/m2, IV day 1, 8 of each 21 day cycle; Oxaliplatin: 70 mg/m2, IV day 1, 8 of each 21 day cycle; Capecitabine: 2x800 mg/m2 PO IV day 1 evening till morning of day 15 of each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops.
Trial: NCT04586907
Drug: LY3537021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT04586907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT02599714
Drug: AZD2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The triplet combination will be comprised of AZD2014 + palbociclib + fulvestrant.
Trial: NCT00002549
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00270959
Drug: FDA-Approved Anti-Anxiety Medications
RxNorm normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.
Trial: NCT01945528
Drug: US-guided tenotomy with PRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood will be drawn from the patient from the patient's unaffected arm. the anti-coagulated blood will be centrifuged and pure-PRP (without leukocytes) collected.~Local anesthetic (lidocaine) will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a single skin portal and multiple longitudinal and transversal penetrations of the tendon will be performed; PRP will be delivered in multiple depots during the procedure
Trial: NCT01449630
Drug: LY3031207
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01449630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01449630
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02430870
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-648 placebo-matching solution
Trial: NCT02979015
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Trial: NCT00105196
Drug: Placebo+ ADT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 2 - 20 mg variable dose once daily, 14 weeks
Trial: NCT03037372
Drug: ART, Rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ART, Rosuvastatin
Trial: NCT03037372
Drug: ART, No statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ART, No statin
Trial: NCT03037372
Drug: Healthy-HIV-negative
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age-matched, Healthy HIV-negative
Trial: NCT02183688
Drug: Low dose ASA
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02183688
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02183688
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01285037
Drug: LY2801653
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2801653 given orally once daily during 28-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
Trial: NCT01361048
Drug: neo penotran forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neo penotran forte intravaginal twice a day for 7 days
Trial: NCT01361048
Drug: neo penotran forte once a day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neo penotran forte intravaginally once a day for 7 days
Trial: NCT03005522
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosed with placebo
Trial: NCT00626223
Drug: folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg per day of oral folic acid
Trial: NCT01423318
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose subcutaneously
Trial: NCT01895296
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo s.c.
Trial: NCT01414881
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously (SC) once weekly
Trial: NCT03960970
Drug: Azithromycin 500 mg
RxNorm normalized name: azithromycin 500 MG
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Additional IV Azithromycin 500 mg to Standard Prophylaxis
Trial: NCT02095860
Drug: DCV 3DAA FDC
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed Dose Combination of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325
Trial: NCT04285749
Drug: Fluvastatin
RxNorm normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluvastatin PO 80mg QD for 2 weeks
Trial: NCT03382548
Drug: Reducing Antibiotics treatment duration
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics should be stopped from day 3 to 7 if respiratory cultures are negative and the patients fulfill a set of stringent clinical criteria signifying cardiopulmonary stability for 48 hours. If the respiratory cultures are positive, patients who fulfill the same set of clinical criteria should have their antibiotics stopped from day 5 to 7.
Trial: NCT03382548
Drug: Standard Antibiotics treatment duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the control (long duration) arm will receive standard care, which is antibiotic treatment for at least 8 days with the exact duration decided by the primary physician.
Trial: NCT00905853
Drug: Escalated Antiarrhythmic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who have 'failed' antiarrhythmic therapy (except amiodarone) will be prescribed: Amiodarone 400 mg twice daily for 2 weeks, followed by 400 mg/day for 4 weeks, followed by 200 mg/day thereafter.~Patients who 'failed' amiodarone (less than 300mg/day) will be prescribed: Amiodarone 400 mg three times a day for 2 weeks, followed by 400 mg/day for 1 week and 300 mg/day thereafter.~Patients who 'failed' amiodarone (greater or equal to 300mg/day) will be prescribed: Amiodarone at the current dose with the addition of mexiletine 400 to 800 mg/day
Trial: NCT02069665
Drug: Xiyanping injection
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.
Trial: NCT02069665
Drug: Xiaoer Qingfei Heji (mixture)
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: children aged 6 months to 1 year old: 10 ml, orally taken three times daily; children aged 1 to 3 year old: 15 ml, orally taken three times daily; children aged 3 to 5 year old: 20 ml, orally taken three times daily;
Trial: NCT02069665
Drug: Zhi Ke San
FDA approved: no
EMA approved: no
PMDA approved: no
Description: children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;
Trial: NCT02069665
Drug: Hua Tan San
FDA approved: no
EMA approved: no
PMDA approved: no
Description: children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;
Trial: NCT02069665
Drug: Ibuprofen Suspension
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: taken under prescription
Trial: NCT00346814
Drug: intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02495844
Drug: UCB0942
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 200 mg Route of Administration: Oral use
Trial: NCT02495844
Drug: UCB0942
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 100 mg Route of Administration: Oral use
Trial: NCT02495844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Film-coated tablet Route of administration: Oral use
Trial: NCT02305758
Drug: Modified FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 180 mg/m\^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m\^2 (90-minute infusion ± 30 minutes); and saline bolus (up to 15-minute infusion) on Day 1 of each 14-day cycle
Trial: NCT02305758
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 180 mg/m\^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m\^2 (90-minute infusion ± 30 minutes); and fluorouracil bolus 400 mg/m\^2 (up to 15-minute infusion) on Day 1 of each 14-day cycle
Trial: NCT02305758
Drug: Fluorouracil infusion
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2400 mg/m\^2 (46-hour continuous infusion ± 4 hours) starting on Day 1 of each 14-day cycle
Trial: NCT01110616
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, to match MK3134, and placebo to match Lorazepam
Trial: NCT02285920
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The trial will be conducted in 2 phases - a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.
Trial: NCT00549939
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form: matching solution or matching tablet according to age~Route: oral~Dose: daily dose adjusted to body weight
Trial: NCT00159757
Drug: ziprazidone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01360554
Drug: Placebo PF00299804
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo PF-00299804, provide as 45 mg tablet, continuous oral daily dosing
Trial: NCT04223843
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Inhalation
Trial: NCT00698724
Drug: Xibrom and Pred Forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xibrom: two drops a day, three days before surgery and 21 days after surgery. Pred Forte: three times a day for 21 days after surgery.
Trial: NCT01312038
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chewable calcium tablet
Trial: NCT01856426
Drug: EDP239
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01856426
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01848340
Drug: 150 mg GSK1265744B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is GSK1265744B (sodium salt of GSK1265744), lactose monohydrate, Microcrystalline cellulose, hypromellose, sodium lauryl sulfate, croscarmellose sodium, magnesium stearate, Opadry film-coating, white OY-S-28876 tablet
Trial: NCT01848340
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcrystalline cellulose, Opadry film-coating, white OY-S-28876 tablet
Trial: NCT04186845
Drug: rhPSMA-7.3 (18F) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioligand for PET CT scanning
Trial: NCT02865122
Drug: NTRA-9620
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral daily dose
Trial: NCT02865122
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral daily dose
Trial: NCT02388620
Drug: LEE011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg
Trial: NCT03093883
Drug: Ferrinemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test product Ferrinemia will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
Trial: NCT00834171
Drug: Loteprednol etabonate (0.5%) and tobramycin (0.3%).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply one or two drops of Loteprednol etabonate (0.5%) and tobramycin (0.3%) into the conjunctival sac as prescribed by your physician.
Trial: NCT02351024
Drug: OXP005
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02351024
Drug: Naprosyn®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01860404
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo solution will have similar taste, texture, consistency and appearance as the BCAA solution.
Trial: NCT01450995
Drug: Imitrex and two Aleve
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imitrex tablet, one tablet dose, Aleve tablets, 2 220 mg tablet dose. Three tablets taken concurrently with migraine onset. Second dose of tablets may be taken if migraine persists for two hours
Trial: NCT03931161
Drug: Placebo Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo for the active comparator (Evolocumab)
Trial: NCT03726866
Drug: Sequence 5
RxNorm normalized name: antihemophilic factor VIII, recombinant porcine sequence 500 (+/-) unit range INTRAVEN VIAL (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D326, D337 or CKD-828 for 9 days
Trial: NCT01356693
Drug: Bromelin
RxNorm normalized name: Bromelin specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ananas comosus extract (3,3g) on vehicle: methylparaben, propylparaben, honey from Apis mellifera, sodium benzoate, ethilic alcohol, water) 5ml. Given in single dose.
Trial: NCT01356693
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with mimicking characteristics of experimental drug
Trial: NCT02332499
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo p.o. qd
Trial: NCT00324168
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: moxifloxacin 0.5% every one hour for 48 hours while awake and then every 2 hours until re-epithelialization
Trial: NCT00324168
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prednisolone phosphate 1% with preservative four times a day for 1 week, then twice a day for 1 week, and finally once a day for 1 week
Trial: NCT04597450
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - capsules, orally, once daily, one capsule will be taken daily for 15 days per treatment period
Trial: NCT00040638
Drug: TLK286
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00324168
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl and preservative (same as in steroid) four times a day for 1 week, then twice a day for 1 week, and finally once a day for 1 week